<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The pathogenesis of <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> (aPL) related <z:mp ids='MP_0005048'>thrombosis</z:mp> is multifactorial and includes, amongst others, enhanced coagulation activation measured as prothrombin fragment 1 + 2 (F1 + 2), elevated plasma levels of <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor (vWF), plasminogen activator inhibitor (PAI) and endothelin-1 (ET-1) as well as heightened <z:chebi fb="0" ids="26995">thromboxane</z:chebi> generation and <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation </plain></SENT>
<SENT sid="1" pm="."><plain>To evaluate the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> susceptibility of some of the above pathways, probucol (500 mg/d orally, a cholesterol lowering agent bearing <z:chebi fb="11" ids="22586">antioxidant</z:chebi> properties) was administered for a three week period to 14 subjects with aPL and to seven healthy controls </plain></SENT>
<SENT sid="2" pm="."><plain>At baseline aPL participants showed higher plasma levels of vWF (P = 0.006), ET-1 (P = 0.0002) and enhanced urinary excretion of <z:chebi fb="0" ids="28667">11-dehydro-thromboxane-B2</z:chebi> (<z:chebi fb="0" ids="28728">TXB2</z:chebi>) (P = 0.0004), F2-isoprostanes (marker of <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation) (P = 0.02) and albumin (P = 0.04) than controls </plain></SENT>
<SENT sid="3" pm="."><plain>In the aPL group baseline IgG anticardiolipin (aCL) titre positively related with urinary <z:chebi fb="0" ids="28728">TXB2</z:chebi> (r2 = 0.43, P = 0.01) and inversely with urinary NOx (r2 = -0.6, P = 0.005) whereas urinary NOx and <z:chebi fb="0" ids="28728">TXB2</z:chebi> were negatively correlated (r2 = -0.42, P = 0.01) </plain></SENT>
<SENT sid="4" pm="."><plain>After the treatment period significant decreases from baseline values were noted for PAI (P = 0.01), ET-1 (P = 0.006), <z:chebi fb="0" ids="28728">TXB2</z:chebi> (P = 0.02), F2-isoprostanes (P = 0.01) and <z:mp ids='MP_0002871'>albuminuria</z:mp> (P = 0.01) in aPL participants but not in controls </plain></SENT>
<SENT sid="5" pm="."><plain>These pilot data support oxidative sensitive mechanisms and a potential role for <z:chebi fb="11" ids="22586">antioxidant</z:chebi> treatment in the pathogenesis of aPL induced vasculopathy </plain></SENT>
</text></document>